Ribociclib for Cancer Patients: Continued Access Study

We are offering patients who previously benefited from ribociclib the chance to continue treatment. This study also aims to collect important safety information about ribociclib alone or with other investigational therapies.

6-10 visits Safety phase (I)Efficacy phase (II)Post-Trial Drug Access No Placebo Investigational Medicines OralOncology

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

What medicines are being studied?

Medicines that are officially approved for use in the European Union and considered safe by EMA. These medicines are already on the market and may be tested for new conditions or populations.

Gefitinib Eg

Gefitinib Eg is a cancer medicine used to treat certain types of non-small cell lung cancer.

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Gefitinib

Gefitinib is a substance that blocks a growth signal in some cancer cells to treat certain non-small cell lung cancers with EGFR mutations.

Ribociclib

Ribociclib is a substance that slows growth of certain breast cancers by blocking proteins that help cancer cells divide.

What experimental substances are being tested?

Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.

Lee011

Nazartinib

What similar medicines might you know?

Don't worry if you don't know the medicines tested in the trial. There is a chance you have heard about the similar medicines. Check the list below to see if you are familiar with any of them.

Gefitiinib Eg

Gefitinib Accord

Gefitinib Arrow

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...

University Hospital Cologne AöR

#1200: Klinik I fuer Innere Medizin

Köln, Germany

Hospital Universitario 12 De Octubre

1301: Oncología

Torrejón de Ardoz, Spain

Sponsor: Novartis Pharma AG

Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.